Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant
Status
Conditions
Details and patient eligibility
About
Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The investigators and others have shown that less toxic preparative regimens (reduced intensity or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions, significantly broadening the population of patients who may be offered this therapy to those who are older and more infirmed. The field is now focusing on the period post transplant for approaches to immune recovery leading to improved outcomes.
The primary objective of this registry is to catalogue data from patients who undergo standard of care reduced intensity allogeneic transplantation.
Full description
Subjects will have toxicity monitored and reported per the Center for International Blood and Marrow Transplant Research (CIBMTR) program standard and as required by law for bone marrow transplant (BMT) reporting in the USA. Data will be collected from physical exam, laboratory studies, radiographs that are performed for clinical purposes. The tests and procedures are not in addition or in excess of our standards for allogeneic transplant outside of this registry. Data about donors will also be collected.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Recipient Inclusion Criteria:
- Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic transplant
Exclusion Criteria:
- Subjects < 18 years of age
- Subjects not undergoing nonmyeloablative or ablative allogeneic transplant
Trial design
48 participants in 1 patient group
Trial contacts and locations
Loading...
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal